Skip to main content
Equibles
LXRX logo

LXRX · Lexicon Pharmaceuticals, Inc. · Metrics

Track LXRX — free

Use LXRX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research LXRX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.88 -0.01 (-0.27%) At close · Sep 30
Russell 2000 member Rebalance outlook locked
Market Cap
$798.70M
Shares
444.96M
Volume · Sep 30 1.74M Avg daily vol (3M) 2.96M

LXRX metrics

70 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.88
Market cap
$798.70M

Price action

20 metrics
Price change (1W)
-13.8%
Price change (30D)
-16.4%
Price change (3M)
-21.7%
Price change (6M)
+20.5%
Price change (YTD)
+63.5%
Price change (1Y)
+35.3%
Trailing year
Price change (5Y)
-61.7%
52-week high
$2.64
52-week low
$1.14
Change from 52-week high
-28.8%
Change from 52-week low
+64.9%
Annualized volatility
77.0%
Annualized volatility (3M)
56.3%
Beta
1.5
RSI (14D)
37.5
Price vs SMA 50
-15.6%
Price vs SMA 200
+2.4%
Avg volume (3M)
3.02M
Relative volume
1.3
Average dollar volume
$6.69M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
444.96M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
15.9×
reciprocal yield 6.3%
EV / EBITDA
—
EV / EBIT
—
P / sales
19.3×
reciprocal yield 5.2%
P / book
4.6
reciprocal yield 21.9%
FCF yield
—
TTM · current market cap
Buyback yield
0.2%
P / FCF
—
P / operating cash flow
—
Earnings yield
-7.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
87.9×
reciprocal yield 1.1%
EV / revenue historical average (5Y)
169.0×
reciprocal yield 0.6%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.2%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
99.1%
Operating margin
-131.4%
Trailing 12 months
Net margin
-147.4%
Gross profit (TTM)
—
Operating profit (TTM)
−$54.50M
Net income (TTM)
−$61.12M
Trailing 12 months
Diluted EPS (TTM)
$-0.15
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.29

Growth

11 metrics
Revenue growth YoY
-97.6%
Year over year
Net income growth YoY
-1,077.1%
Revenue (TTM)
$41.47M
Trailing 12 months
EPS growth YoY
-800.0%
Shares change YoY
+20.4%
Year over year · more shares
Revenue CAGR (3Y)
+610.3%
Revenue CAGR (5Y)
+15.7%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-35.0%
Return on assets
-24.4%
Debt / equity
0.3
Current ratio
13.4
EBITDA (TTM)
−$54.02M
Free cash flow (TTM)
—
Quick ratio
13.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$139.17M
Latest balance sheet
Cash & equivalents
$40.92M
Total assets
$250.06M
Total debt
$51.44M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$64.99M
Capital expenditures (TTM)
—
R&D (TTM)
$60.27M
SG&A (TTM)
$35.34M
Stock compensation (TTM)
$12.69M
R&D / revenue
145.3%
Stock compensation / revenue
30.6%

Ownership (13F)

3 metrics
13F filers
150
13F filer change QoQ
+13
Institutional ownership
82.3%

Short interest

3 metrics
Short interest
6.5%
Latest settlement · 13.4 days to cover
Days to cover
13.4d
Short-squeeze score
65 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1062822 CUSIP 528872302 13F (30d) 4 filings 4 filers Visit website Investor relations